Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Sparingvision, Centre National De La Recherche Scienfitique - Crns -, Sorbonne Universite
InventorsDeniz DALKARA, Hanen KHABOU, Florence LORGET, José SAHEL, Simon CARDILLA-JOE
Estimating the term…
The present invention relates to the combination of a nucleic acid encoding a short isoform of rod-derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic acid encoding a G protein-activated Inward Rectifier potassium channel 2 (GIRK2), expressed through one, two or three viral vectors, said vectors may be within a single pharmaceutical composition or within several different pharmaceutical compositions (two or three). It also deals with the treatment of a retinal degenerative disease, in particular the retinitis pigmentosa, with said viral vectors or pharmaceutical compositions.
A pharmaceutical composition comprising one or several viral vectors, wherein said one or several viral vectors comprise a nucleic acid encoding a short isoform of rod-derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic acid encoding a G protein-activated Inward Rectifier potassium channel 2 (GIRK2).
A viral vector comprising three nucleic acids respectively encoding RdCVF, RdCVFL and GIRK2.
A kit comprising two pharmaceutical compositions, wherein:
A kit comprising three pharmaceutical compositions, wherein:
Dependencies are inferred from the claim text.